Opioid Epidemic/Drug Policy

The United States is in experiencing dramatic increases in the use of prescription and illicit opioid drugs. The amfAR policy office is committed to reducing the risk of acquiring HIV and hepatitis C, improving treatment outcomes, and advocating for harm reduction policies to improve outcomes for people who inject drugs. The policy office maintains a database of epidemiological, policy, and funding data on opioid use, HIV, and hepatitis C.

New Study Suggests Most Substance Abuse Facilities Don’t Test for HIV

220 Vulnerable Counties: One Year Later

amfAR Study Assesses Impact of Medicaid Expansion on the Opioid Epidemic

amfAR Report Highlights Huge Gaps in Access to Opioid Addiction Treatment

 

Syringe Services Programs and the Opioid Epidemic

Issue Brief: The Case for Supervised Consumption Services  

Preventing HIV and Hepatitis Infections Among People Who Inject Drugs: Leveraging an Indiana Outbreak Response to Break the Impasse

Special Report: Harm Reduction and the Global HIV Epidemic

Lack of Syringe Services Programs Adds Up to Big Costs (Infographic)

Issue Brief: Preventing HIV and Hepatitis C Among People Who Inject Drugs: Public Funding for Syringe Services Programs Makes the Difference